Bcl-2 may play a role in the progression of endometrial hyperplasia and early carcinogenesis, but not linked to further tumorigenesis. Issue 1 (March 2015)

• Record Type: Journal Article
• Authors: Laban, Mohamed; Ibrahim, Eman Abdel-Salam; Agur, Wael; Ahmed, Ahmed M. Bahaaa Elddin
• Is Part Of: Journal of microscopy and ultrastructure. Volume 3:Issue 1(2015)
• Page Start: 19
• Page End: 24
• Publication Date: 2015-03
• Subjects: Microscopy -- Periodicals; 502.8205
• DOI: 10.1016/j.jmau.2014.11.001
• Languages: English
• ISSNs: 2213-879X

Abstract

<abstract abstract-type="author" id="abs0005"> <title id="sect0005">Abstract</title> <sec> <p id="spar0005">The role of Bcl-2 in initiation and progression of endometrial carcinoma is still with inconsistent results. The aim of this study is to determine the role of Bcl-2 in endometrial tumorigenesis. It is a retrospective cross sectional study. We used 100 endometrial paraffin embedded specimens for Bcl-2 oncoprotein immunohistochemical staining; 20 samples of normal endometrium, 40 specimens of endometrial hyperplasia (simple, complex and atypical) and 40 specimens of endometrioid adenocarcinoma. The results were statistically analyzed. There was a significant increase in Bcl-2 staining from normal through complex and atypical hyperplasia into well differentiated adenocarcinoma (<italic>P</italic> = 0.002, <italic>P</italic> = 0.0008 and <italic>P</italic> = 0.0001, respectively). There was a significant difference between the staining of different types of endometrial hyperplasia; as it up streamed from the simple through the complex up to the atypical types (<italic>P</italic> < 0.05). Bcl-2 staining showed no significant correlation with the moderately, poorly differentiated and the different stages of adenocarcinoma (<italic>P</italic> = 0.6, <italic>P</italic> = 0.29 and <italic>P</italic> = 0.1 respectively).</p> <p id="spar0010">These results might indicate a substantial role for Bcl-2 as one of the initiating drives for endometrial tumorigenesis, but not in further tumor progression.</p> </sec> </abstract>